seekingalpha.com
WuXi AppTec Co., Ltd. (WUXAY) Presents at 44th Annual J.P.
WuXi AppTec Co., Ltd. (WUXAY) Presents at 44th Annual J.P.
WUXIFWUXIFOTC
Loading
Latest News
Loading news...
defenseworld.net
WuXi AppTec (OTCMKTS:WUXIF) Shares Up 1.6% – Time to Buy?
Shares of WuXi AppTec Co., Ltd. (OTCMKTS:WUXIF - Get Free Report) rose 1.6% during trading on Tuesday. The stock traded as high as $15.00 and last traded at $15.00. Approximately 600 shares traded hands during trading, a decline of 87% from the average daily volume of 4,656 shares. The stock had previously closed at
prnewswire.com
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry
SHANGHAI, MIDDLETOWN, Del. and MUNICH , Nov. 19, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost & Sullivan with the 2025 Global Company of the Year Award in the CRDMO industry.
benzinga.com
China's Corporate Pivots: Alibaba's Food Delivery Gambit and WuXi AppTec's Geopolitical Hedge
Two recent, seemingly unrelated corporate maneuvers offer a telling glimpse into the strategic pivots major Chinese companies are making in response to shifting consumer habits and global political currents. In one corner is e-commerce giant Alibaba (NYSE: BABA) (9988.HK), which is overhauling its local delivery strategy by retiring a household brand.
prnewswire.com
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash dividends.
prnewswire.com
WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled
SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced the completion of its second RMB1.0 billion A-share repurchase program in 2025 to enhance shareholder value, with all repurchased shares to be cancelled.
prnewswire.com
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year
SHANGHAI , Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year. This recognition underscores the Company's ongoing commitment to sustainable development and its efforts to build a healthier, more sustainable world.
reuters.com
China's Wuxi Apptec to raise over $980 million to boost expansion
Wuxi Apptec said on Thursday it will be raising HK$7.70 billion ($980.98 million) through a share placement to aid its global expansion plans.
seekingalpha.com
WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript
WuXi AppTec Co., Ltd. (OTCPK:WUXIF) Q2 2025 Earnings Conference Call July 28, 2025 9:00 PM ET Company Participants Ming Shi - Senior VP & CFO Minzhang Chen - Co-CEO & Executive Director Qing Yang - Co-CEO & Executive Director Ruijia Tang - IR Director Conference Call Participants Laurence Tam - Morgan Stanley, Research Division Laurence Tam Good morning.
prnewswire.com
WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
SHANGHAI , July 10, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and manufacturing services, has issued a Positive Profit Alert for the first half of 2025 and disclosed key operational data forecasts.
prnewswire.com
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
SHANGHAI , July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently provided updates to investors on the status of its A-share repurchase and H-share acquisition activities in Q2 2025.
prnewswire.com
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
SHANGHAI , June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popular Choice Winner in the "Factory & Warehouse" category at the 2025 Architizer A+Awards. This recognition underscores WuXi AppTec's commitment to creating innovative, human-centric workplaces that empower employees and support customers in delivering transformative therapies for patients.
prnewswire.com
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI , June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science-based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuXi AppTec's commitment to meaningful action for a more sustainable future.
reuters.com
Focus: China pharma projects disrupted by Sino-US tensions
Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of U.S.-China trade tensions.
prnewswire.com
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI , June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been recognized among the Top 10 "Most Honored Companies" in new rankings from Extel (formerly known as Institutional Investor). WuXi AppTec was chosen from more than 1,600 companies across 18 industries in Extel's 2025 Executive Team rankings for companies in Asia (ex-Japan/ANZ).
seekingalpha.com
prnewswire.com
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI , Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, underscoring the company's enduring commitment to responsible business practices and supply chain resilience. The PSCI is a leading global non-profit membership association for pharmaceutical and healthcare companies that drives responsible value chains through its three modes of impact: Audit, Capability, and Projects.
prnewswire.com
WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating
COUVET, Switzerland , Nov. 14, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec's steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities into its strategy and operations.
prnewswire.com
WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
SHANGHAI , Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a growth advisory firm. This marks the eighth consecutive year that WuXi AppTec has achieved this distinction.